Cargando…

New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide

Daily 20-μg and once-weekly 56.5-μg teriparatide (parathyroid hormone 1–34) treatment regimens increase bone mineral density (BMD) and prevent fractures, but changes in bone turnover markers differ between the two regimens. The aim of the present study was to explain changes in bone turnover markers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Sakae, Adachi, Taiji, Kuroda, Tatsuhiko, Nakamura, Toshitaka, Shiraki, Masataka, Sugimoto, Toshitsugu, Takeuchi, Yasuhiro, Saito, Mitsuru, Bilezikian, John P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472137/ https://www.ncbi.nlm.nih.gov/pubmed/26273530 http://dx.doi.org/10.1038/boneres.2014.43

Ejemplares similares

Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide
por: Takeuchi, Yasuhiro, et al.
Publicado: (2015)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
por: Sugimoto, Toshitsugu, et al.
Publicado: (2017)

Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
por: Shiraki, Masataka, et al.
Publicado: (2021)

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
por: Sugimoto, T., et al.
Publicado: (2013)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
por: Mori, Satoshi, et al.
Publicado: (2022)

The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT
por: Ito, M., et al.
Publicado: (2013)

Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study
por: Sugimoto, Toshitsugu, et al.
Publicado: (2021)

How different is the once-weekly teriparatide from the daily one or the same?
por: Takeuchi, Yasuhiro
Publicado: (2019)

Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study
por: Kuroda, Tatsuhiko, et al.
Publicado: (2021)

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Once-weekly teriparatide increases bone mineral density in the distal 1/10 radius, but not in the distal 1/3 radius
por: Urushibara, Nobuo, et al.
Publicado: (2014)

Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis
por: Fujita, Takuo, et al.
Publicado: (2013)

Utility of radius bone densitometry for the treatment of osteoporosis with once-weekly teriparatide therapy
por: Nakayama, Harumi, et al.
Publicado: (2018)

Therapy of Osteoporosis in Men with Teriparatide
por: Cusano, Natalie E., et al.
Publicado: (2011)

A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05
por: Hagino, H., et al.
Publicado: (2021)

Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX
por: Harvey, N. C., et al.
Publicado: (2015)

Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk
por: Ifuku, Emiko, et al.
Publicado: (2019)

Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
por: Nanki, Toshihiro, et al.
Publicado: (2022)

Nonsurgical Corrective Union of Osteoporotic Vertebral Fracture with Once-Weekly Teriparatide
por: Miyakoshi, Naohisa, et al.
Publicado: (2015)

Impact of patient background factors on the treatment efficacy of once-weekly teriparatide
por: Omura, Fumitoshi
Publicado: (2019)

Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial‐05 (JOINT‐05)
por: Tanaka, Shiro, et al.
Publicado: (2022)

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
por: Shiraki, M., et al.
Publicado: (2012)

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
por: Lau, Arthur N, et al.
Publicado: (2010)

Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice‐Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single‐Blind Randomized Study
por: Kumagai, Yuji, et al.
Publicado: (2019)

Nitric oxide is associated with fracture risk in Japanese women
por: Shiraki, Masataka, et al.
Publicado: (2023)

Effects of treatment interruption due to patient convenience on treatment of once a week teriparatide
por: Katahira, Genichiro, et al.
Publicado: (2020)

Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007)

Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis
por: Fujita, Ryo, et al.
Publicado: (2022)

Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
por: Nakamura, Toshitaka, et al.
Publicado: (2014)

Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary
por: Orimo, Hajime, et al.
Publicado: (2012)

Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012)

Association between elcatonin use and cancer risk in Japan: A follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis
por: Okamoto, Hiroaki, et al.
Publicado: (2020)

Weekly Teriparatide Therapy Rapidly Accelerates Bone Healing in Pyogenic Spondylitis with Severe Osteoporosis
por: Shinohara, Akira, et al.
Publicado: (2014)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Teriparatide for osteoporosis: importance of the full course
por: Lindsay, R., et al.
Publicado: (2016)

Treatment of osteoporosis with teriparatide: The Slovenian experience
por: Kocjan, Tomaz, et al.
Publicado: (2021)

Prediction of Fracture Risk From Early‐Stage Bone Markers in Patients With Osteoporosis Treated With Once‐Yearly Administered Zoledronic Acid
por: Kasai, Hidefumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ng1mtpq1s63lmjk0aosh03n9fm